In 2023, Hawaii had the lowest death rate from cancer among all U.S. states, with around 119 deaths per 100,000 population. The states with the highest cancer death rates at that time were Kentucky, West Virginia, and Mississippi. This statistic shows cancer death rates in the United States in 2023, by state.

In 2022, Kentucky reported the highest cancer incidence rate in the United States, with around 512 new cases of cancer per 100,000 inhabitants. This statistic represents the U.S. states with the highest cancer incidence rates per 100,000 population in 2022.

In 2021, there were around *** new cases of breast cancer per 100,000 population in the state of Connecticut, making it the state with the highest breast cancer incidence rate that year. This statistic shows the incidence rate of breast cancer in the U.S. in 2021, by state.

In 2022, Utah had the lowest death rate from cancer among all U.S. states with around 116 deaths per 100,000 population. The states with the highest cancer death rates at that time were Mississippi, Kentucky and West Virginia. This statistic shows cancer death rates in the United States in 2022, by state.

In 2022, there were 157 cases of prostate cancer per 100,000 population in the state of Louisiana, making it the state with the highest prostate cancer incidence rate that year. This statistic shows the incidence rate of prostate cancer in the U.S. in 2022, by state.

What are Cancer Statistics in US States?

The circled group of good survivors has genetic indicators of poor survivors (i.e. low ESR1 levels, which is typically the prognostic indicator of poor outcomes in breast cancer) – understanding this group could be critical for helping improve mortality rates for this disease. Why this group survived was quickly analysed by using the Outcome Column (here Event Death - which is binary - 0,1) as a Data Lens (which we term Supervised vs Unsupervised analyses).

How to use this dataset

• A network was built using only gene expression with 272 breast cancer patients (as rows), and 1570 columns.

• Metadata includes patient info, treatment, and survival.

• Each node is a group of patients similar to each other. Flares (left) represent sub-populations that are distinct from the larger population. (One differentiating factor between the two flares is estrogen expression (low = top flare, high = bottom flare)).

• A bottom flare is a group of patients with 100% survival. The top flare shows a range of survival – very poor towards the tip (red), and very good near the base (circled).

Acknowledgments

When we use this dataset in our research, we credit the authors as :

• License : CC BY 4.0.

• This data set is taken from https://query.data.world/s/yi422lv7mkhnydnt4ixrfujmoaglpk .

The main idea for uploading this dataset is to practice data analysis with my students, as I am working in college and want my student to train our studying ideas in a big dataset, It may be not up to date and I mention the collecting years, but it is a good resource of data to practice

In 2023, there were **** deaths from breast cancer per 100,000 population in the state of South Dakota, the lowest of any state that year. This statistic shows the death rate from breast cancer in the U.S. in 2023, by state.

ObjectiveTriple negative breast cancer (TNBC) is a more aggressive subtype resistant to conventional treatments with a poorer prognosis. This study was to update the status of TNBC and the temporal changes of its incidence rate in the US.MethodsWomen diagnosed with breast cancer during 2011–2019 were obtained from the National Program of Cancer Registries (NPCR) and Surveillance, Epidemiology and End Results (SEER) Program SEER*Stat Database which covers the entire population of the US. The TNBC incidence and its temporal trends by race, age, region (state) and disease stage were determined during the period.ResultsA total of 238,848 (or 8.8%) TNBC women were diagnosed during the study period. TNBC occurred disproportionally higher in women of Non-Hispanic Black, younger ages, with cancer at a distant stage or poorly/undifferentiated. The age adjusted incidence rate (AAIR) for TNBC in all races decreased from 14.8 per 100,000 in 2011 to 14.0 in 2019 (annual percentage change (APC) = −0.6, P = 0.024). Incidence rates of TNBC significantly decreased with APCs of −0.8 in Non-Hispanic White women, −1.3 in West and −0.7 in Northeastern regions. Women with TNBC at the age of 35–49, 50–59, and 60–69 years, and the disease at the regional stage displayed significantly decreased trends. Among state levels, Mississippi (20.6) and Louisiana (18.9) had the highest, while Utah (9.1) and Montana (9.6) had the lowest AAIRs in 2019. New Hampshire and Indiana had significant and highest decreases, while Louisiana and Arkansas had significant and largest increases in AAIR. In individual races, TNBC displayed disparities in temporal trends among age groups, regions and disease stages. Surprisingly, Non-Hispanic White and Hispanic TNBC women (0–34 years), and Non-Hispanic Black women (≥70 years) during the entire period, as well as Asian or Pacific Islander women in the South region had increased trends between 2011 and 2017.ConclusionOur study demonstrates an overall decreased trend of TNBC incidence in the past decade. Its incidence displayed disparities among races, age groups, regions and disease stages. Special attention is needed for a heavy burden in Non-Hispanic Black and increased trends in certain groups.

In 2016 in India during the measured time period, Kerala had the highest crude incidence rate of cancer at ***** incidences for every 100,000 inhabitants. Mizoram in East India followed with almost *** incidences during the same time period.

MMWR Surveillance Summary 66 (No. SS-1):1-8 found that nonmetropolitan areas have significant numbers of potentially excess deaths from the five leading causes of death. These figures accompany this report by presenting information on potentially excess deaths in nonmetropolitan and metropolitan areas at the state level. They also add additional years of data and options for selecting different age ranges and benchmarks. Potentially excess deaths are defined in MMWR Surveillance Summary 66(No. SS-1):1-8 as deaths that exceed the numbers that would be expected if the death rates of states with the lowest rates (benchmarks) occurred across all states. They are calculated by subtracting expected deaths for specific benchmarks from observed deaths. Not all potentially excess deaths can be prevented; some areas might have characteristics that predispose them to higher rates of death. However, many potentially excess deaths might represent deaths that could be prevented through improved public health programs that support healthier behaviors and neighborhoods or better access to health care services. Mortality data for U.S. residents come from the National Vital Statistics System. Estimates based on fewer than 10 observed deaths are not shown and shaded yellow on the map. Underlying cause of death is based on the International Classification of Diseases, 10th Revision (ICD-10) Heart disease (I00-I09, I11, I13, and I20–I51) Cancer (C00–C97) Unintentional injury (V01–X59 and Y85–Y86) Chronic lower respiratory disease (J40–J47) Stroke (I60–I69) Locality (nonmetropolitan vs. metropolitan) is based on the Office of Management and Budget’s 2013 county-based classification scheme. Benchmarks are based on the three states with the lowest age and cause-specific mortality rates. Potentially excess deaths for each state are calculated by subtracting deaths at the benchmark rates (expected deaths) from observed deaths. Users can explore three benchmarks: “2010 Fixed” is a fixed benchmark based on the best performing States in 2010. “2005 Fixed” is a fixed benchmark based on the best performing States in 2005. “Floating” is based on the best performing States in each year so change from year to year. SOURCES CDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov). REFERENCES Moy E, Garcia MC, Bastian B, Rossen LM, Ingram DD, Faul M, Massetti GM, Thomas CC, Hong Y, Yoon PW, Iademarco MF. Leading Causes of Death in Nonmetropolitan and Metropolitan Areas – United States, 1999-2014. MMWR Surveillance Summary 2017; 66(No. SS-1):1-8. Garcia MC, Faul M, Massetti G, Thomas CC, Hong Y, Bauer UE, Iademarco MF. Reducing Potentially Excess Deaths from the Five Leading Causes of Death in the Rural United States. MMWR Surveillance Summary 2017; 66(No. SS-2):1–7.

IntroductionLiver cancer is the fastest increasing cancer in the United States and is one of the leading causes of cancer-related death in New York City (NYC), with wide disparities among neighborhoods. The purpose of this cross-sectional study was to describe liver cancer incidence by neighborhood and examine its association with risk factors. This information can inform preventive and treatment interventions.Materials and methodsPublicly available data were collected on adult NYC residents (n = 6,407,022). Age-adjusted data on liver and intrahepatic bile duct cancer came from the New York State Cancer Registry (1) (2007–2011 average annual incidence); and the NYC Vital Statistics Bureau (2015, mortality). Data on liver cancer risk factors (2012–2015) were sourced from the New York City Department of Health and Mental Hygiene: (1) Community Health Survey, (2) A1C registry, and (3) NYC Health Department Hepatitis surveillance data. They included prevalence of obesity, diabetes, diabetic control, alcohol-related hospitalizations or emergency department visits, hepatitis B and C rates, hepatitis B vaccine coverage, and injecting drug use.ResultsLiver cancer incidence in NYC was strongly associated with neighborhood poverty after adjusting for race/ethnicity (β = 0.0217, p = 0.013); and with infection risk scores (β = 0.0389, 95% CI = 0.0088–0.069, p = 0.011), particularly in the poorest neighborhoods (β = 0.1207, 95% CI = 0.0147–0.2267, p = 0.026). Some neighborhoods with high hepatitis rates do not have a proportionate number of hepatitis prevention services.ConclusionHigh liver cancer incidence is strongly associated with infection risk factors in NYC. There are gaps in hepatitis prevention services like syringe exchange and vaccination that should be addressed. The role of alcohol and metabolic risk factors on liver cancer in NYC warrants further study.

Cancer was responsible for around *** deaths per 100,000 population in the United States in 2023. The death rate for cancer has steadily decreased since the 1990’s, but cancer still remains the second leading cause of death in the United States. The deadliest type of cancer for both men and women is cancer of the lung and bronchus which will account for an estimated ****** deaths among men alone in 2025. Probability of surviving Survival rates for cancer vary significantly depending on the type of cancer. The cancers with the highest rates of survival include cancers of the thyroid, prostate, and testis, with five-year survival rates as high as ** percent for thyroid cancer. The cancers with the lowest five-year survival rates include cancers of the pancreas, liver, and esophagus. Risk factors It is difficult to determine why one person develops cancer while another does not, but certain risk factors have been shown to increase a person’s chance of developing cancer. For example, cigarette smoking has been proven to increase the risk of developing various cancers. In fact, around ** percent of cancers of the lung, bronchus and trachea among adults aged 30 years and older can be attributed to cigarette smoking. Other modifiable risk factors for cancer include being obese, drinking alcohol, and sun exposure.

BackgroundForty percent of new cancer cases in the United States are attributed to modifiable risks, which can be influenced by the built environment. Recent cancer prevention guidelines include recommendations for making communities conducive to healthy living. Focused on the city of Philadelphia, the present study aims to 1) evaluate neighborhood-level adherence to cancer prevention guidelines by developing two novel indices and 2) identify factors driving low compliance in neighborhoods with high cancer mortality.MethodsPhiladelphia neighborhoods were compared to the city overall on ten cancer prevention recommendations. Comparison scores informed two indices: one focused on the American Cancer Society’s guidelines for Physical Activity, Nutrition, and Smoking, and the other focused on Healthy People 2030’s guidelines for Prevention Services. Indices were mapped by neighborhood and compared to cancer mortality. Where low adherence overlapped with high cancer mortality, the recommendations driving low compliance were identified.ResultsDistinct geospatial patterns were observed in adherence to guidelines, and while drivers of low adherence varied by neighborhood, general trends emerged in different areas of the city. Concerning Physical Activity, Nutrition, and Smoking Guideline adherence, some areas appeared to be more influenced by the built environment, while others were impacted by specific behavioral risk factors such as excessive alcohol consumption. Preventive Service recommendation adherence was driven in some parts by self-reported poor health and, in others, low cancer screening rates and a high physician-to-resident ratio. In neighborhoods where poor guideline adherence overlapped with high cancer mortality, the built environment emerged as a potentially important factor.DiscussionThis study considers the importance of the built environment in influencing adherence to cancer prevention guidelines. Policymakers and public health officials can use this information to prioritize interventions for neighborhoods with low guideline adherence and high cancer burden and tailor interventions to focus on indicators of low guideline adherence.

Cervical cancer (CC) is a public health problem with a high disease burden and mortality in developing countries. In Brazil, areas with low human development index have the highest incidence rates of Brazil and upward temporal trend for this disease. The Northeast region has the second highest incidence of cervical cancer (20.47 new cases / 100,000 women). In this region, the mortality rates are similar to rates in countries that do not have a health system with a universal access screening program, as in Brazil. Thus, this study aimed to analyze the effects of age, period and birth cohorts on mortality from cervical cancer in the Northeast region of Brazil. Estimable functions predicted the effects of age, period and birth cohort. The average mortality rate was 10.35 deaths per 100,000 women during the period analyzed (1980–2014). The highest mortality rate per 100,000 women was observed in Maranhão (24.39 deaths), and the lowest mortality rate was observed in Bahia (11.24 deaths). According to the period effects, only the state of Rio Grande do Norte showed a reduction in mortality risk in the five years of the 2000s. There was a reduction in mortality risk for birth cohorts of women after the 1950s, except in Maranhão State, which showed an increasing trend in mortality risk for younger generations. We found that the high rates of cervical cancer mortality in the states of northeastern Brazil remain constant over time. Even after an increase in access to health services in the 2000s, associated with increased access to the cancer care network, which includes early detection (Pap Test), cervical cancer treatment and palliative care. However, it is important to note that the decreased risk of death and the mortality rates from CC among women born after the 1960s may be correlated with increased screening coverage, as well as increased access to health services for cancer treatment observed in younger women.

According to cognitive market research, the global lung cancer therapeutics market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

The lungs are two spongy organs in the chest that control breathing. Lung cancer is the leading cause of cancer deaths worldwide. People who smoke have the greatest risk of lung cancer. The risk of lung cancer increases with the length of time and number of cigarettes smoked.
The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals
The chemotherapy segment dominated the lung cancer therapeutics market revenue in 2024 and is projected to be the fastest-growing segment during the forecast period. Chemotherapy goes throughout the entire body for tumor cells, whereas radiation and surgery target a single region of the body.
Moreover, this market dominance is a result of consumers' growing propensity to buy pharmaceuticals from hospital pharmacies due to the availability of a large variety of medicines.
There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the instruments adds up to the total cost.

Market Dynamics of the Lung Cancer Therapeutics

Key Drivers of the Lung Cancer Therapeutics

The strong prevalence of lung cancer is notably driving market growth.

One of the most prevalent forms of cancer is lung cancer. Several reasons, including the aging population and lifestyle changes, have contributed to a notable increase in the number of new instances of cancer, particularly lung cancer, in recent years. In the United States, 6.2% of the population is at risk of developing lung cancer. Lung cancer still has a very high death rate, even with recent declines in the rate, which presents a market potential for suppliers. The market is anticipated to expand over the forecast period as a result of the high disease incidence rate and the rising number of drug approvals. • For instance, according to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of color at 20%. Hence, the increasing prevalence of cancer and the need for effective treatment is likely to contribute to market growth. (Source:https://www.lung.org/research/state-of-lung-cancer/key-findings)

Rising pollution due to rapid industrialization increases the incidences of lung cancer

Air pollution (outdoor and indoor particulate matter and ozone) is closely linked to the rising prevalence of heart disease and strokes, lung cancer, lower respiratory infections, diabetes, and chronic obstructive pulmonary disease (COPD). The Global Burden of Disease Study Report (2019) ranks air pollution as the third leading cause of death worldwide. Globally, air pollution is responsible for 6.82 million deaths annually, of which 33% are caused by interior pollution and 66% by outdoor pollution. • For instance, According to the conference organized by the Associated Chambers of Commerce and Industry of India (ASSOCHAM), ‘Lung Cancer- Awareness, Prevention, Challenges & Treatment’, air pollution is the leading cause of the rise of lung cancer in the country. Around 63 out of the 100 most polluted places on earth belong to India. (Source:https://www.assocham.org/press-release-page.php?release-name=air-pollution-is-the-major-cause-of-lung-cancer-in-india-say-health-experts)

Restraints of the Lung Cancer Therapeutics

Regional disparities in treatment will hamper the market for lung cancer therapeutics

Lung cancer is the most prevalent cause of cancer-related deaths globally, and its impact is particularly felt in lower- and middle-income countries (LMICs), where access to early and effective diagnosis and treatment is often restricted. WHO data show that whereas 90% of cancer patients in high-income countries have access to therapy, only roughly 30% of cancer patients in low-income countries do. There are numerous products involved in the procedure of lung cancer therapeutics, which makes it costlier. Furthermore, the high maintenance cost of the i...

In the United States, medically underserved women carry a heavier burden of cancer incidence and mortality, yet are largely underrepresented in cancer prevention studies. My Body, My Test is a n observational cohort, multi-phase cervical cancer prevention study in North Carolina that recruited low-income women, aged 30–65 years and who had not undergone Pap testing in ≥ 4 years. Participants were offered home-based self-collection of cervico-vaginal samples for primary HPV testing. Here, we aimed to describe the recruitment strategies utilized by study staff, and the resulting recruitment and self-collection kit return rates for each specific recruitment strategy. Participants were recruited through different approaches: either direct (active, staff-effort intensive) or indirect (passive on the part of study staff). Of a total of 1,475 individuals screened for eligibility, 695 were eligible (47.1%) and 487 (70% of eligible) participants returned their self-collection kit. Small media recruitment resulted in the highest number of individuals found to be study eligible, with a relatively high self-collection kit return of 70%. In-clinic in-reach resulted in a lower number of study-eligible women, yet had the highest kit return rate (90%) among those sent kits. In contrast, 211 recruitment which resulted in the lowest kit return of 54%. Small media, word of mouth, and face-to-face outreach resulted in self-collection kit return rates ranging from 72 to 79%. The recruitment strategies undertaken by study staff support the continued study of reaching under-screened populations into cervical cancer prevention studies.

The global breast cancer therapy market, valued at $30.70 billion in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 7.17% from 2025 to 2033. This expansion is fueled by several key factors. Rising breast cancer incidence rates globally, particularly in developing nations, are driving demand for effective therapies. Advancements in targeted therapies, such as Herceptin, Tykerb (Lapatinib), and Afinitor, are improving treatment outcomes and patient survival rates, further stimulating market growth. The increasing prevalence of early detection programs and improved diagnostic techniques contribute to earlier interventions and a higher demand for treatment. Furthermore, ongoing research and development efforts focused on innovative therapies, including immunotherapy and personalized medicine approaches, are poised to significantly impact market expansion in the coming years. Competition among established pharmaceutical companies and emerging biotech firms is also fostering innovation and accessibility to advanced treatments. However, market growth is subject to certain restraints. High treatment costs associated with advanced therapies, including targeted therapies and immunotherapy, pose a significant barrier for many patients globally. Access to these treatments remains unequal across regions, particularly in low- and middle-income countries, impacting the overall market penetration. The development of drug resistance, a common challenge in cancer treatment, necessitates continuous innovation and the development of novel therapies to maintain treatment effectiveness. Regulatory hurdles and lengthy approval processes for new drugs also represent potential challenges to market expansion. Despite these constraints, the consistent growth in the number of breast cancer diagnoses, combined with the continuous development of more effective and targeted treatments, assures a positive outlook for this dynamic market sector. The market's segmentation into various therapies – radiation therapy, targeted therapy, hormonal therapy, and chemotherapy – allows for tailored treatment approaches based on individual patient needs, further driving overall market growth. Recent developments include: In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC)., In August 2022, the United States Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is one of the first approved therapies targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.. Key drivers for this market are: High Incidence and Prevalence Rate of Breast Cancer, Increasing Investments in R&D; Advancements in Cancer Biology and Pharmacology, Promoting Drug Development. Potential restraints include: High Incidence and Prevalence Rate of Breast Cancer, Increasing Investments in R&D; Advancements in Cancer Biology and Pharmacology, Promoting Drug Development. Notable trends are: Chemotherapy Segment Expected to Witness High Growth Over the Forecast Period.

These are the data used to generate Figure 2 in the manuscript, "The relationship between cancer incidence, stage, and poverty in the United States". The variable 'count' represents the actual single year case counts in the areas included in the study (16 states+Los Angeles) projected to the entire US. The variable 'countnopov' represents the expected case counts were all persons to be in the lowest poverty category, all other things being equal.

In 2021, Utah had the highest rate of skin cancer, with an estimated ** people out of 100,000 diagnosed with melanoma or another non-epithelial skin cancer. This statistic shows the incidence rate of skin cancer in the U.S. in 2021, by state, per 100,000 population.

Neighborhoods with overlap of worst preventive services guideline adherence and highest cancer mortality.